Biosect, I am usually right there with you defending them and will revert back to doing so if they get the data out soon. I am not sure if I am part of where these comments are directed or not. I don’t really care and don’t hold grudges. You know that Regulatory process and manufacturing are not linked to publication process after the SAP has been filed.
IMO they have handled RA well, Advent manufacturing build out well (not so much regarding Cognate and the 875 million CRL paid for Cognate a few years ago for basically our investment proves that to me), and financial survival well too but after the Cognate investment BS. TLD release…not so much. If they miss SNO, then IMO not at all. If they had extensive pharmaceutical experience on their small team, then I could be talked into giving them more time, but they don’t.
COVID Schmovid at this point as well. After meeting with one KOL last week, he told me that he would be spending the next day and weekend reviewing a dozen submissions for publication, like he usually dose twice a month. They are dealing with white collar, work from home stuff now with regards to TLD. COVID is not a reasonable excuse any more. It is not impacting Congress presentation or publications. Things are back to normal now, and have been with regards to publication for a long time now. If they try to use it again, they will lose support.
While I think a steady drum beat of positive news will help lift this stock to where it should be at this point in the game, I don’t buy the argument at all that shorts can pick apart a Late-breaker plenary presentation more than they can a publication. If new money plans to join the party, that will begin after a successful presentation. It does not have to be timed with manufacturing news or regulatory news. Major congress presentation of pivotal trial data gets the attention and support of the target market and can stand alone as fuel for attracting investment. The thing about publicity is that you want as much of it as you can get. Limiting yourself to publication, limits the number of substantive PRs and the attention from both the medical community and the investment community.
Cliches are cliches because they are usually true…and ‘there is no such thing as bad publicity’ (especially if that is based on positive news).
